ELI LILLY AND COMPANY (NYSE:LLY) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition
ELI LILLY AND COMPANY (NYSE:LLY) Files An 8-K Results of Operations and Financial Condition
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Attached as Exhibit 99.1>and incorporated by reference into this Item 2.02 is a copy of the press release, dated April 25, 2017, announcing our results of operations for the first quarter and three-month period ended March 31, 2017, including, among other things, unaudited operating results for such period.
Item 9.01. Financial Statements and Exhibits
Exhibit Number Description
99.1 Press release dated April 25, 2017 together with related attachments.
About ELI LILLY AND COMPANY (NYSE:LLY)
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company’s animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products. ELI LILLY AND COMPANY (NYSE:LLY) Recent Trading Information
ELI LILLY AND COMPANY (NYSE:LLY) closed its last trading session up +1.53 at 83.42 with 4,813,568 shares trading hands.
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company’s animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products. ELI LILLY AND COMPANY (NYSE:LLY) Recent Trading Information
ELI LILLY AND COMPANY (NYSE:LLY) closed its last trading session up +1.53 at 83.42 with 4,813,568 shares trading hands.
